Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. The report has identified the 6 Key Large Opportunities in this space and developed market forecasts.
The report has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. The report summarizes what technologies they are using.
Make investment decisions and valuations with confidence using the latest data. The report includes five-year market forecasts.
Key Topics Covered:
Overview of a Dynamic Market
- Market Players - Roles & Impacts
- Understanding Antimicrobial Resistance
- The Changing Road to New Antibiotics & Technologies
- The Key Role of Diagnostics in AMR
The Key Large Market Opportunities in AMR
- Streptococcus Pneumoniae (DRSP)
- Campylobacter (DRC)
- Clostridium Difficile (CD)
- Staphylococcus aureus (MRSA)
- Neisseria gonorrhoeae (DRNG)
- Salmonella (DRNTS)
Therapeutic Technology Development Opportunities
- Using Viruses Against Bacteria
- Hydrolytic Enzymes Join the Fight
- Antibodies
- Vaccines
- Probiotic Technology
- Peptides vs. Pathogens
- Mining Obsolete Science
- CRISPR Antibiotics
Antibiotic Resistance Recent Developments
- Bacteriophage May Combat AMR
- Shionogi to Acquire Qpex Biopharma
- Adaptive Phage Therapeutics to Fight Antibiotic Resistance
- Smartbax to create next-generation antibiotics
- Startup Solu raises €1M to combat AMR
- Akthelia Pharma and University of Iceland to Combat AMR
- WHO warns of too few new Antibiotics
- Bactobio Raises £6 Million To Discover Novel Antimicrobials
- AMR triggers race to develop phages
- AMR Pandemic Overlooked
- New resistance-busting antibiotic combination
- CDC Awards $22M to Combat Antimicrobial Resistance
- Antibiotic resistance outwitted by supercomputers
- STIs Reach Record Highs
- New research using nanoparticles to bolster waning antibiotics
- OpGen Receives FDA Clearance for AMR Panel
- CDC Updates STI Diagnosis, Treatment Guidelines
- Positive associations between AM use in animals and AMR in humans
- PEW Antibiotic Pipeline Findings
Key Biotechnology Companies and Their Technology
- Melinta Therapeutics
- Arsanis
- Phage Technologies S.A
- Westway Health
- Tetraphase Pharmaceuticals
- BioVersys GmbH
- Nabriva Therapeutics
- Macrolide Pharmaceuticals
- Nemesis Bioscience
- C3J Therapeutics, Inc.
- EpiBiome
- discuva
- SmartPhage.
- AmpliPhi Biosciences
- Pherecydes Pharma
- Micreos
- Procarta Biosystems
- Lumavita
- Madam Therapeutics
- Priaxon
- Biolytx Pharmaceuticals
- AntibioTx
- Xellia Pharmaceutials
- Paratek Pharmaceuticals
- Synereca Pharmaceuticals
- Allecra Therapeutics
- Fixed Phage
- Enanta Pharmaceuticals, Inc.
- Demuris
- Prommune
- Biosergen
- Innovation Pharmaceuticals
- Aviragen Therapeutics
- Achillion Pharmaceuticals
- ImmunNovative Developments, S.L.
- Achaogen, Inc.
- SelectX Pharmaceuticals, Inc.
- TaiGen Biotechnology Co., Ltd.
- Theravance Biopharma
- Abbvie
- KYORIN Pharmaceutical Co.,Ltd.
- Iterum Therapeutics Limited
- Forge Therapeutics
- Alopexx Vaccine LLC
- Integrated Biotherapeutics
- Hennepin Life Sciences
- Fedora Pharmaceuticals Inc.
- Contrafect Corporation
- Basilea Pharmaceutica Ltd.
- AiCuris
- RedHill Biopharma
- Redx Pharma Plc/Redx Anti Infectives Ltd.
- ABAC Therapeutics
- Alaxia SAS
- Antabio S.A.S
- Auspherix Ltd
- BioFilm Pharma
- Centauri Therapeutics Ltd
- Combioxin SA
- Da Volterra
- Debiopharm International SA
- Deinobiotics/Deinove
- Destiny Pharma plc
- Eligo Bioscience
- Helperby Therapeutics Ltd
- Karveel Pharmaceuticals
- MaaT Pharma
- Motif BioSciences, Inc/Motif Bio PLC
- Mutabilis SAS
- Neem Biotech Ltd
- Northern Antibiotics Oy (Ltd)
- Nosopharm
- NovaBiotics Ltd
- Phico Therapeutics Ltd
- Polyphor Ltd
- QureTech Bio AB
- SetLance srl
- Ultupharma AB
- Vaxdyn
- Vibiosphen
- Bioaster
- Vivexia
- KBP Biosciences
- Absynth Biologics
- Spero Therapeutics
- Merck
- Symphogen
- Warp Drive Bio.
- Johnson & Johnson (Janssen)
- Pfizer
- Allergan
- GlaxoSmithKline
- Novartis
- Gilead Sciences
- AstraZeneca
- Sanofi
- Shionogi Inc.
- Cipla
- DSM Sinochem Pharmaceuticals
- Wockhardt Ltd.
- VenatoRx Pharmaceuticals
- MicuRx
- Entasis Therapeutics
- Merlion Pharmaceuticals
- Aridis Pharmaceuticals Inc.
Market Sizes by Pathogen
- DRSP Market
- DRC Market
- CD Market
- MRSA Market
- DRNG Market
- DRNTS Market
- Other Pathogen Market
The Future of AMR
For more information about this report visit https://www.researchandmarkets.com/r/km7mm3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
